NCT06694350View on ClinicalTrials.gov

Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

Pembrolizumab+Flutamide

Pembrolizumab 200mg ivgtt once +Flutamide 250mg，Q8h

All Listed Sponsors

lead

Zhejiang Provincial People's Hospital

OTHER